Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Bakhos A. Tannous is active.

Publication


Featured researches published by Bakhos A. Tannous.


Cancer Cell | 2008

miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells

Thomas Wurdinger; Bakhos A. Tannous; Okay Saydam; Johan Skog; Stephan Grau; Jürgen Soutschek; Ralph Weissleder; Xandra O. Breakefield; Anna M. Krichevsky

A key step in angiogenesis is the upregulation of growth factor receptors on endothelial cells. Here, we demonstrate that a small regulatory microRNA, miR-296, has a major role in this process. Glioma cells and angiogenic growth factors elevate the level of miR-296 in primary human brain microvascular endothelial cells in culture. The miR-296 level is also elevated in primary tumor endothelial cells isolated from human brain tumors compared to normal brain endothelial cells. Growth factor-induced miR-296 contributes significantly to angiogenesis by directly targeting the hepatocyte growth factor-regulated tyrosine kinase substrate (HGS) mRNA, leading to decreased levels of HGS and thereby reducing HGS-mediated degradation of the growth factor receptors VEGFR2 and PDGFRbeta. Furthermore, inhibition of miR-296 with antagomirs reduces angiogenesis in tumor xenografts in vivo.


Nature Methods | 2008

A secreted luciferase for ex-vivo monitoring of in vivo processes

Thomas Wurdinger; Christian E. Badr; Lisa Pike; Ruben de Kleine; Ralph Weissleder; Xandra O. Breakefield; Bakhos A. Tannous

Luciferases are widely used to monitor biological processes. Here we describe the naturally secreted Gaussia princeps luciferase (Gluc) as a highly sensitive reporter for quantitative assessment of cells in vivo by measuring its concentration in blood. The Gluc blood assay complements in vivo bioluminescence imaging, which has the ability to localize the signal and provides a multifaceted assessment of cell viability, proliferation and location in experimental disease and therapy models.


Cancer Research | 2011

Human Glioma Growth Is Controlled by MicroRNA-10b

Galina Gabriely; Ming Yi; Ravi S. Narayan; Johanna M. Niers; Thomas Wurdinger; Jaime Imitola; Keith L. Ligon; Santosh Kesari; Christine Esau; Robert M. Stephens; Bakhos A. Tannous; Anna M. Krichevsky

MicroRNA (miRNA) expression profiling studies revealed a number of miRNAs dysregulated in the malignant brain tumor glioblastoma. Molecular functions of these miRNAs in gliomagenesis are mainly unknown. We show that inhibition of miR-10b, a miRNA not expressed in human brain and strongly upregulated in both low-grade and high-grade gliomas, reduces glioma cell growth by cell-cycle arrest and apoptosis. These cellular responses are mediated by augmented expression of the direct targets of miR-10b, including BCL2L11/Bim, TFAP2C/AP-2γ, CDKN1A/p21, and CDKN2A/p16, which normally protect cells from uncontrolled growth. Analysis of The Cancer Genome Atlas expression data set reveals a strong positive correlation between numerous genes sustaining cellular growth and miR-10b levels in human glioblastomas, while proapoptotic genes anticorrelate with the expression of miR-10b. Furthermore, survival of glioblastoma patients expressing high levels of miR-10 family members is significantly reduced in comparison to patients with low miR-10 levels, indicating that miR-10 may contribute to glioma growth in vivo. Finally, inhibition of miR-10b in a mouse model of human glioma results in significant reduction of tumor growth. Altogether, our experiments validate an important role of miR-10b in gliomagenesis, reveal a novel mechanism of miR-10b-mediated regulation, and suggest the possibility of its future use as a therapeutic target in gliomas.


Molecular and Cellular Biology | 2009

Downregulated MicroRNA-200a in Meningiomas Promotes Tumor Growth by Reducing E-Cadherin and Activating the Wnt/beta-Catenin Signaling Pathway

Okay Saydam; Yiping Shen; Thomas Wurdinger; Ozlem Senol; Elvan Boke; Marianne James; Bakhos A. Tannous; Anat Stemmer-Rachamimov; Ming Yi; Robert M. Stephens; Cornel Fraefel; James F. Gusella; Anna M. Krichevsky; Xandra O. Breakefield

ABSTRACT Meningiomas, one of the most common human brain tumors, are derived from arachnoidal cells associated with brain meninges, are usually benign, and are frequently associated with neurofibromatosis type 2. Here, we define a typical human meningioma microRNA (miRNA) profile and characterize the effects of one downregulated miRNA, miR-200a, on tumor growth. Elevated levels of miR-200a inhibited meningioma cell growth in culture and in a tumor model in vivo. Upregulation of miR-200a decreased the expression of transcription factors ZEB1 and SIP1, with consequent increased expression of E-cadherin, an adhesion protein associated with cell differentiation. Downregulation of miR-200a in meningiomas and arachnoidal cells resulted in increased expression of β-catenin and cyclin D1 involved in cell proliferation. miR-200a was found to directly target β-catenin mRNA, thereby inhibiting its translation and blocking Wnt/β-catenin signaling, which is frequently involved in cancer. A direct correlation was found between the downregulation of miR-200a and the upregulation of β-catenin in human meningioma samples. Thus, miR-200a appears to act as a multifunctional tumor suppressor miRNA in meningiomas through effects on the E-cadherin and Wnt/β-catenin signaling pathways. This reveals a previously unrecognized signaling cascade involved in meningioma tumor development and highlights a novel molecular interaction between miR-200a and Wnt signaling, thereby providing insights into novel therapies for meningiomas.


Nature Protocols | 2009

Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo

Bakhos A. Tannous

Secreted reporters are a useful tool in the monitoring of different biological processes in the conditioned medium of cultured cells as well in the blood and urine of experimental animals. Described here is a protocol for detecting the recently established naturally secreted Gaussia luciferase (Gluc) in cultured cells as well as in blood and urine in vivo. Furthermore, the assay for detecting the secreted alkaline phosphatase (SEAP), the most commonly used secreted reporter in serum, is also presented. The Gluc reporter system has several advantages over the SEAP assay, including a much reduced assay time (1–10 min versus 1.5–2 h), 20,000-fold (in vitro) or 1,000-fold (in vivo) increased sensitivity and a linear range covering over five orders of magnitude of cell number. Additionally, the Gluc signal can be detected in urine and the signal can be localized in animals using in vivo bioluminescence imaging.


Cancer Cell | 2010

In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in Glioblastoma

Shahryar E. Mir; Philip C. De Witt Hamer; Przemek M. Krawczyk; Leonora Balaj; An Claes; Johanna M. Niers; Angela A.G. van Tilborg; Aeilko H. Zwinderman; Dirk Geerts; Gertjan J. L. Kaspers; W. Peter Vandertop; Jacqueline Cloos; Bakhos A. Tannous; Pieter Wesseling; Jacob A. Aten; David P. Noske; Cornelis J. F. Van Noorden; Thomas Wurdinger

Kinases execute pivotal cellular functions and are therefore widely investigated as potential targets in anticancer treatment. Here we analyze the kinase gene expression profiles of various tumor types and reveal the wee1 kinase to be overexpressed in glioblastomas. We demonstrate that WEE1 is a major regulator of the G(2) checkpoint in glioblastoma cells. Inhibition of WEE1 by siRNA or small molecular compound in cells exposed to DNA damaging agents results in abrogation of the G(2) arrest, premature termination of DNA repair, and cell death. Importantly, we show that the small-molecule inhibitor of WEE1 sensitizes glioblastoma to ionizing radiation in vivo. Our results suggest that inhibition of WEE1 kinase holds potential as a therapeutic approach in treatment of glioblastoma.


Cancer Cell | 2015

RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics

Myron G. Best; Nik Sol; Irsan E. Kooi; Jihane Tannous; Bart A. Westerman; François Rustenburg; Pepijn Schellen; Heleen Verschueren; Edward Post; Jan Koster; Bauke Ylstra; Najim Ameziane; Josephine C. Dorsman; Egbert F. Smit; Henk M.W. Verheul; David P. Noske; Jaap C. Reijneveld; R. Jonas A. Nilsson; Bakhos A. Tannous; Pieter Wesseling; Thomas Wurdinger

Summary Tumor-educated blood platelets (TEPs) are implicated as central players in the systemic and local responses to tumor growth, thereby altering their RNA profile. We determined the diagnostic potential of TEPs by mRNA sequencing of 283 platelet samples. We distinguished 228 patients with localized and metastasized tumors from 55 healthy individuals with 96% accuracy. Across six different tumor types, the location of the primary tumor was correctly identified with 71% accuracy. Also, MET or HER2-positive, and mutant KRAS, EGFR, or PIK3CA tumors were accurately distinguished using surrogate TEP mRNA profiles. Our results indicate that blood platelets provide a valuable platform for pan-cancer, multiclass cancer, and companion diagnostics, possibly enabling clinical advances in blood-based “liquid biopsies”.


ACS Nano | 2014

Dynamic Biodistribution of Extracellular Vesicles in Vivo Using a Multimodal Imaging Reporter

Charles P. Lai; Osama Mardini; Maria Ericsson; Shilpa Prabhakar; Casey A. Maguire; John W. Chen; Bakhos A. Tannous; Xandra O. Breakefield

Extracellular vesicles (EVs) are nanosized vesicles released by normal and diseased cells as a novel form of intercellular communication and can serve as an effective therapeutic vehicle for genes and drugs. Yet, much remains unknown about the in vivo properties of EVs such as tissue distribution, blood levels, and urine clearance, important parameters that will define their therapeutic effectiveness and potential toxicity. Here we combined Gaussia luciferase and metabolic biotinylation to create a sensitive EV reporter (EV-GlucB) for multimodal imaging in vivo, as well as monitoring of EV levels in the organs and biofluids ex vivo after administration of EVs. Bioluminescence and fluorescence-mediated tomography imaging on mice displayed a predominant localization of intravenously administered EVs in the spleen followed by the liver. Monitoring EV signal in the organs, blood, and urine further revealed that the EVs first undergo a rapid distribution phase followed by a longer elimination phase via hepatic and renal routes within six hours, which are both faster than previously reported using dye-labeled EVs. Moreover, we demonstrate systemically injected EVs can be delivered to tumor sites within an hour following injection. Altogether, we show the EVs are dynamically processed in vivo with accurate spatiotemporal resolution and target a number of normal organs as well as tumors with implications for disease pathology and therapeutic design.


Trends in Biotechnology | 2011

Bioluminescence imaging: progress and applications

Christian E. Badr; Bakhos A. Tannous

Application of bioluminescence imaging has increased tremendously in the past decade and has significantly contributed to core conceptual advances in biomedical research. This technology provides valuable means for monitoring of different biological processes in immunology, oncology, virology and neuroscience. In this review, we discuss current trends in bioluminescence and its application in different fields with an emphasis on cancer research.


Nature Neuroscience | 2015

A neural basis for melanocortin-4 receptor regulated appetite

Alastair S. Garfield; Chia Yen Li; Joseph C. Madara; Bhavik P. Shah; Emily Webber; Jennifer S. Steger; John N. Campbell; Oksana Gavrilova; Charlotte E. Lee; David P. Olson; Joel K. Elmquist; Bakhos A. Tannous; Michael J. Krashes; Bradford B. Lowell

Pro-opiomelanocortin (POMC)- and agouti-related peptide (AgRP)-expressing neurons of the arcuate nucleus of the hypothalamus (ARC) are oppositely regulated by caloric depletion and coordinately stimulate and inhibit homeostatic satiety, respectively. This bimodality is principally underscored by the antagonistic actions of these ligands at downstream melanocortin-4 receptors (MC4R) in the paraventricular nucleus of the hypothalamus (PVH). Although this population is critical to energy balance, the underlying neural circuitry remains unknown. Using mice expressing Cre recombinase in MC4R neurons, we demonstrate bidirectional control of feeding following real-time activation and inhibition of PVHMC4R neurons and further identify these cells as a functional exponent of ARCAgRP neuron–driven hunger. Moreover, we reveal this function to be mediated by a PVHMC4R→lateral parabrachial nucleus (LPBN) pathway. Activation of this circuit encodes positive valence, but only in calorically depleted mice. Thus, the satiating and appetitive nature of PVHMC4R→LPBN neurons supports the principles of drive reduction and highlights this circuit as a promising target for antiobesity drug development.

Collaboration


Dive into the Bakhos A. Tannous's collaboration.

Top Co-Authors

Avatar

Thomas Wurdinger

VU University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David P. Noske

VU University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

W. Peter Vandertop

VU University Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge